MSB Draws US$15 Million From Existing Facility
Filed with ASX · · 2 pages · English
Earlier from Mesoblast
- P3 Trial of MSBs Cell Therapy in CHF Completes Recruitment
- Response to ASX query
- LVAD Results Webcast Presentation
- LVAD Trial Results Provide Potential Regulatory Pathway
- MSB Expands Partnership With JCR For Skin Disease
Later from Mesoblast
- MSB Licensee Files For Skin Disease Marketing Approval
- MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
- Mesoblast Initiates Rolling Submission of BLA for GvHD
- MSB Provides Q3 Financial Results and Operational Highlights
- MSB Expands JCR Partnership To Brain Disease In Newborns
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast